SOPHiA GENETICS (NASDAQ:SOPH) CTO Sells $38,261.44 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CTO Abhimanyu Verma sold 6,944 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $5.51, for a total transaction of $38,261.44. Following the transaction, the chief technology officer directly owned 197,456 shares of the company’s stock, valued at approximately $1,087,982.56. This trade represents a 3.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Abhimanyu Verma also recently made the following trade(s):

• On Tuesday, April 7th, Abhimanyu Verma sold 1,030 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.87, for a total value of $5,016.10.
• On Monday, April 6th, Abhimanyu Verma sold 2,519 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.86, for a total value of $12,242.34.

SOPHiA GENETICS Price Performance

NASDAQ:SOPH traded up $0.06 during trading hours on Friday, reaching $5.75. 423,880 shares of the company traded hands, compared to its average volume of 174,550. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.06 and a quick ratio of 1.90. The firm’s 50-day moving average is $5.06 and its 200-day moving average is $4.92. The stock has a market cap of $482.37 million, a P/E ratio of -11.06 and a beta of 0.98. SOPHiA GENETICS SA has a 1-year low of $2.81 and a 1-year high of $5.94.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The company had revenue of $21.69 million during the quarter, compared to analyst estimates of $20.40 million.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Tuesday, April 21st. BTIG Research reiterated a “buy” rating and set a $8.00 price target on shares of SOPHiA GENETICS in a report on Monday, June 15th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $7.50.

Institutional Investors Weigh In On SOPHiA GENETICS

A number of hedge funds and other institutional investors have recently made changes to their positions in SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in SOPHiA GENETICS by 246.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after purchasing an additional 5,432,871 shares during the last quarter. Akre Capital Management LLC boosted its stake in SOPHiA GENETICS by 66.2% in the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after buying an additional 1,481,636 shares during the last quarter. Hodges Capital Management Inc. purchased a new stake in SOPHiA GENETICS in the 1st quarter valued at about $2,157,000. Royce & Associates LP purchased a new stake in SOPHiA GENETICS in the 4th quarter valued at about $2,009,000. Finally, Sei Investments Co. purchased a new stake in SOPHiA GENETICS in the first quarter valued at approximately $1,772,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.